IV. Sales of Entresto® rising steadily upon the Class I recommendation by the European and American heart failure guideline
Novartis announced on May 21, 2016 that the Guideline for the Management of Heart Failure recently updated by the American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) and European Society of Cardiology (ESC) gave a Class I recommendation for Entresto® in treating heart failure.
The guideline updated by ACC/AHA/HFSA recommended "Entresto®+ β-receptor blocker+ aldosterone antagonist" as the standard therapy for patients with heart failure and reduced ejection fraction, to serve as an alternative to the conventional angiotensin converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) drugs for heart failure. The guideline of ACC/AHA/HFSA recommended patients with mild to moderate heart failure who are tolerant to ACE or ARB to change to use Entresto®.
In the Europe, ESC also updated the Guidelines for the diagnosis and treatment of acute and chronic heart failure based on the results of PARADIGM-HF study, and recommended patients with mild to moderate heart failure who have stable condition but poor blood pressure control, and are tolerant to ACE or ARB to change to use Entresto® for treatment.
Sales of Entresto® rose with the recommendation by clinical guidelines: the sales of Entresto® in 2017 Q2 reached USD 110 million, according to the quarterly report of Novartis.
Fig. 1 Sales Situation of Entresto® in Recent Years

In addition, according to Elevatepharm’s forecast on Entresto® sales, the sales of Entresto® will reach USD 4.881 billion in 2022, hopefully to become the top 1 on the heart disease drug market.
Fig. 2 Elevatepharm’s Forecast on Sales of Entresto® in the Next 6 Years

V. Guess of price of Entresto® on the Chinese market
The guess of the market price of Entresto® is made mainly based on the daily treatment expense of the current gold standard regimen and the price situation of the new heart failure drug: Ivabradine Hydrochloride in China.
Calculation of the daily treatment expense of current gold standard regimen
Heart failure is mainly treated with drug combination. The daily treatment expense of the gold standard therapeutic regimen for patients is calculated according to the pharmaceutical product retail prices:
Recent Bid-winning Prices of Drugs in the Gold Standard Regimen for Heart Failure










(All Rights Reserved)